Anticholinergics for symptomatic management of Parkinson´s disease

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2002, Pages

  Katzenschlager, Regina ^a   Sampaio, Cristina ^b   Costa, João ^b   Lees, Andrew ^c  

^a DANUBE HOSPITAL   (Austria)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85122317628     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003735     Document Type: Review

References (28)

1. Brumlik J, Canter G, De la Torre R, Mier M, Petrovick M, Boshes B. A critical analysis of the effects of trihexyphenidyl (artane) on the components of the parkinsonian syndrome. J Nerv Ment Dis 1964;138:424-431.
2. Cantello R, Riccio A, Gilli M, Delsedime M, Scarzella L, Aguggia M, Bergamasco B. Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients. Ital J Neurol Sci 1986;7:139-143.
3. Iivainen M. KR 339 in the treatment of parkinsonian tremor. Acta Neurol Scand 1974;50:469-470.
4. Kaplan HA, Machover S, Rabiner A. A study of the effectiveness of drug therapy in parkinsonism. J Nerv Dis 1954;119:398-411.
5. Norris JW, Vas CJ. Mehixene hydrochloride and parkinsonian tremor. Acta Neurol Scand 1967;43:535-538.
6. Piccirilli M, D'Alessandro P, Testa A, Piccinin GL, Agostini L. [Il bornaprine nel trattamento del tremore parkinsoniano]. Riv Neurol 1985;55:38-45.
7. Tourtelotte WW, Potvin AR, Syndulko K, Hirsch SB, Gilden ER, Potvin JH, Hansch EC. Parkinson's disease: Cogentin with sinemet, a better response. Prog Neuro-Psychopharmacol & Biol Psychiat 1982;6:51-55.
8. Vicary DJ, Horrocks PM, Rees JE, Parkes JD, Marsden CD. The treatment of patients with Parkinson's disease receiving levodopa. A comparison of benapryzine (brizine) and benzhexol. Clin Trials J 1973;1:3-6.
9. Whyte RK, Hunter KR, Laurence DR, Stern GM, Armitage P. Levodopa and orphenadrine hydrochloride in parkinsonism. Europ J Clin Pharmacol 1971;4:18-21.
10. Couto B, Oliveira C, Mattos JP, Freitas MR. The L-dopa sparing effect of G 31,406 in the treatment of Parkinson's disease. Neurol Neurocir Psiquiatr 1976;17:285-292.
11. Iivainen M. [Kr 399 Parkinsonismivapinan hoidossa]. Duodecim 1972;90:590-596.
12. Martin WE, Loewenson RB, Resch JA, Baker AB. A controlled study comparing trihexiphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease. Neurology 1974;24:912-919.
13. Rix A. Evaluation of an experimental anticholinergic drug, elantrine, in treating the tremor of parkinsonism. Adv Exp Med Biol 1977;90:277-281.
14. Strang RR. Double-blind clinical evaluation of UCB 1549 in treatment of Parkinson's disease. Brit Med J 1966;2:1112-1113.
15. Birket-Smith E. Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurol Scand 1974;50:801-811.
16. Birket-Smith E. Abnormal involuntary movements in relation to anticholinergics and levodopa therapy. Acta Neurol Scand 1975;52:158-160.
17. De Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y. Confusion, dementia, and anticholinergics in Parkinson´s disease. J Neurol Neurosurg Psychiatry 1982;45:1161-1164.
18. Dixon RA, Munro JF, Sicocks PB. Evidence based medicine workbook.
19. Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role?. Neurology 1977;27:783-790.
20. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y. Cholinergic-dependent cognitive deficits in Parkinsons´disease. Ann Neurol 1987;22:26-30.
21. Goetz CG, Nausiedad PA, Weines PH, Klawans HL. Practical guidelines for drug holidays in parkinsonian patients. Neurology 1981;31:641-642.
22. Horrocks PM, Vicary DJ, Rees JE, Parkes JD, Marsden CD. Anticholinergic withdrawal and benzhexol treatment in Parkinson´s disease. J Neurol Neurosurg Psychiatry 1973;36:936-941.
23. Hughes RC, Polgar JG, Weightman D, Walton JN. Levodopa in parkinsonism: the effects of withdrawal of anticholinergic drugs. Brit Med J 1971;2:487-491.
24. Lang AE, Blair RDG. Anticholinergic drugs and amantadine in the treatment of Parkinson´s disease. In: Calne DB editor(s). Handbook pf experimental pharmacology. Vol. 88, Berlin Heidelberg: Springer Verlag, 1989.
25. Ordenstein L. Sur la paralyse agitante et la sclerose en plaques generalisee. Paris: Martinet, 1867; p 32.
26. Sadeh M, Braham J, Modan M. Effects of anticholinergic drugs on memory in Parkinson´s disease. Arch Neurol 1982;39:666-667.
27. Syndulko K, Gilden ER, Hansch EC, Potvin AR, Tourtelotte WW, Povin JH. Decreased verbal memory associated with anticholinergic treatment in Parkinson´s disease patients. Int J Neurosci 1981;14:61-66.
28. Webster DD. Clinical analysis of the disability in Parkinson's disease. Modern Treatment 1968;5:257-82.